Laboratory Corporation of America Holdings (LH) 116.90 $LH
MWI Veterinary: Benefits of Takeover by AmerisourceBergen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:58PM CST
On Feb 11, 2015, we issued an updated research report on MWI Veterinary Supply Inc. (MWIV).
ABC: 100.34 (+0.51), MWIV: 189.72 (-0.17), CAH: 86.08 (+0.04), LH: 116.90 (+0.06)
Laboratory Corp of America Holdings Has Returned 11.1% Since SmarTrend Recommendation (LH)
Comtex SmarTrend(R) - Thu Feb 12, 10:31AM CST
SmarTrend identified an Uptrend for Laboratory Corp of America Holdings (NYSE:LH) on December 1st, 2014 at $104.33. In approximately 2 months, Laboratory Corp of America Holdings has returned 11.08% as of today's recent price of $115.90.
LH: 116.90 (+0.06)
'Opportunity Strategy' - 6 Months Of Trading Rationale And Analysis
Grey Owl Capital - Seeking Alpha - Thu Feb 12, 1:01AM CST
"Never think that lack of variability is stability. Don't confuse lack of volatility with stability, ever." - Nassim Nicholas Taleb Over the past seven months the price of oil has plunged from a peak above $100/barrel to the mid-$40s...
LUK: 23.50 (-0.01), DNOW: 25.64 (+0.70), EXC: 33.51 (-0.93), UPL: 15.67 (+0.84), NOV: 53.36 (+0.80), POST: 48.62 (-0.25), COG: 28.10 (+0.18), BAX: 70.39 (+0.31), AAL: 48.39 (+0.51), LH: 116.90 (+0.06), ENB: 49.37 (-0.22), VWO: 41.78 (+0.42), BRG: 13.65 (+0.31), BRK.B: 148.34 (-1.45), AAPL: 127.08 (+0.62)
Teledyne Technologies Set to Join the S&P MidCap 400; Popeyes Louisiana Kitchen, Iridium Communications to Join the S&P SmallCap 600
PR Newswire - Tue Feb 10, 5:04PM CST
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
DRIV: 25.99 (+0.06), IRDM: 9.46 (+0.11), TDY: 100.91 (+1.11), LH: 116.90 (+0.06), MHFI: 102.19 (unch), PLKI: 61.07 (+0.44), CVD: 107.08 (+0.05)
LabCorp Launches New Patient-Centric Diabetes Report
Business Wire - Tue Feb 10, 7:45AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today the availability of a new Diabetes Patient Education report for type 2 diabetes patients that aligns with the American Diabetes Association (Association) "Standards of Medical Care in Diabetes - 2015," which was published as a supplement to the January 2015 edition of the Association's Diabetes Care journal. LabCorp's Diabetes Patient Education report is a patient-specific education tool that graphically displays results for key tests used to monitor diabetes and its complications, such as hemoglobin A1c (HbA1c), LDL cholesterol, and urine albumin. The report provides, in patient-friendly terms, guidance to help understand test results and suggestions on how to maintain or improve diabetes control and overall cardiovascular risk, focusing on dietary and lifestyle changes. These reports can be conveniently ordered by clinicians treating patients with elevated HbA1c results or a diagnosis of type 2 diabetes. The reports are part of a suite of decision support tools available from LabCorp to assist clinicians and patients in the management of common chronic diseases, such as cardiovascular disease, chronic kidney disease and now, type 2 diabetes.
LH: 116.90 (+0.06)
Watch for Laboratory Corp of America Holdings to Potentially Rebound After Falling 1.33% Yesterday
Comtex SmarTrend(R) - Mon Feb 09, 5:04PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $113.01 to a high of $115.23. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $114.72 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 116.90 (+0.06)
Look for Shares of Laboratory Corp of America Holdings to Potentially Rebound after Yesterday's 1.33% Sell Off
Comtex SmarTrend(R) - Mon Feb 09, 5:03PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $113.01 to a high of $115.23. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $114.72 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 116.90 (+0.06)
Steris Tops Q3 Earnings, Revenues; Cuts FY15 Top-Line View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:54AM CST
Steris Corp. (STE) reported third-quarter fiscal 2015 adjusted earnings of 79 cents per share, up 33.9% from the year-ago level.
STE: 65.50 (-0.35), CAH: 86.08 (+0.04), LH: 116.90 (+0.06), MMSI: 17.27 (-0.16)
Becton, Dickinson Beats Q1 Earnings, Revenue Outlook Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:48AM CST
Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2015 EPS of $1.53, which beat the Zacks Consensus Estimate by a dime.
BDX: 143.71 (+0.72), CAH: 86.08 (+0.04), LH: 116.90 (+0.06), MMSI: 17.27 (-0.16)
Covance Earnings in Line, LabCorp Merger Awaits Closure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:36AM CST
Covance (CVD) delivered a healthy performance in the quarter, breaking all prior records, specifically with fourth quarter adjusted net orders amounting to $823 million.
ABCO: 53.69 (+0.32), BEAT: 10.36 (+0.20), LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Covance Reports Fourth Quarter Net Revenue Of $634 Million, Pro Forma EPS Of $0.97 And Record Adjusted Net Orders Of $823 Million
PR Newswire - Wed Feb 04, 6:30AM CST
Covance Inc. (NYSE: CVD) today reported results for its fourth quarter ended December 31, 2014. Net revenue was $634 million, representing 1.8% growth on a GAAP basis from the fourth quarter of 2013. When adjusting for the impact of foreign exchange and the divestitures of the Seattle genomics laboratory and antibody products service line and the acquisition of Medaxial in 2014, revenue growth was 5.3% versus the fourth quarter of 2013. On a GAAP basis, the company reported earnings of $0.91 per diluted share in the fourth quarter. The company reported pro forma earnings per diluted share of $0.97, up 11.9% over the fourth quarter of 2013. Pro forma results exclude charges associated with restructuring and other cost reduction actions and expenses incurred in connection with the planned merger with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) totaling $5.6 million or $0.06 per share.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Icon, A Leader In Its Industry, Builds A Base
at Investor's Business Daily - Tue Jan 27, 5:12PM CST
New drugs require clinical trials and those trials increasingly have taken place on an international stage. Many top drug developers outsource an increasing share of trials to companies like Icon (ICLR). Based in Dublin, Icon is one of the top five...
PRXL: 62.91 (-0.18), Q: 63.31 (+0.06), LH: 116.90 (+0.06), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
LabCorp plans sale of senior notes in four tranches
M2 - Thu Jan 22, 7:10AM CST
Diagnostic technologies company Laboratory Corporation of America Holdings (NYSE:LH) said on Wednesday that it intends to issue senior notes in four tranches with maturities of five,seven,ten and 30 years, respectively (the notes).
LH: 116.90 (+0.06)
LabCorp prices debt offering
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 6:20AM CST
LH: 116.90 (+0.06)
LabCorp Prices $500,000,000 in 2.625% Senior Notes Due 2020, $500,000,000 in 3.200% Senior Notes Due 2022, $1,000,000,000 in 3.600% Senior Notes Due 2025 and $900,000,000 in 4.700% Senior Notes Due 2045
Business Wire - Wed Jan 21, 6:41PM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that it has priced its offering of $2.9 billion in senior notes. The offering consists of four tranches: $500,000,000 aggregate principal amount of 2.625% Senior Notes due 2020 (the "2020 Notes"
, $500,000,000 aggregate principal amount of 3.200% Senior Notes due 2022 (the "2022 Notes" , $1,000,000,000 aggregate principal amount of 3.600% Senior Notes due 2025 (the "2025 Notes" and $900,000,000 aggregate principal amount of 4.700% Senior Notes due 2045 (together with the 2020 Notes, the 2022 Notes and the 2025 Notes, the "Notes" . The Notes will bear interest from January 30, 2015, payable semi-annually on February 1 and August 1, commencing on August 1, 2015. The closing of the offering is expected to occur on January 30, 2015, subject to the satisfaction of customary closing conditions. The Notes will be senior unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
LabCorp Announces Proposed Sale of Senior Notes
Business Wire - Wed Jan 21, 7:59AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in four tranches with maturities of 5,7,10 and 30 years, respectively (the "Notes" . The Notes will be senior unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Technical Snapshot on Health Care Services Stocks -- Express Scripts Holding, Quest Diagnostics, Laboratory Corp. of America, Catamaran, and DaVita HealthCare Partners
PR Newswire - Wed Jan 21, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Express Scripts Holding Company (NASDAQ: ESRX), Quest Diagnostics Inc. (NYSE: DGX), Laboratory Corporation of America Holdings (NYSE: LH), Catamaran Corporation (NASDAQ: CTRX), and DaVita HealthCare Partners Inc. (NYSE: DVA). Free research report on Express Scripts Holding can be accessed at http://get.Investor-Edge.com/pdf/?c=Express%2...amp;s=ESRX. On Tuesday, January 20, 2015, the NASDAQ Composite ended at 4,654.85, up 0.44%, the Dow Jones Industrial Average advanced 0.02%, to finish the day at 17,515.23, and the S&P 500 closed at 2,022.55, up 0.15%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.01, down 0.08%, while the index has advanced 14.99% in the previous three months. Register for your complimentary reports at the links given below.
CTRX: 53.24 (+0.65), ESRX: 84.90 (+0.40), DVA: 73.10 (-3.29), DGX: 71.68 (+0.03), LH: 116.90 (+0.06)
Upgrade Alert for Laboratory Corp of America Holdings (LH)
Comtex SmarTrend(R) - Wed Jan 21, 7:03AM CST
Laboratory Corp of America Holdings (NYSE:LH) was upgraded from Hold to Buy at Evercore ISI today. The stock closed yesterday at $117.23 on volume of 1.1 million shares, below average daily volume of 1.5 million. Laboratory Corp of America Holdings (NYSE:LH) is currently priced 4.3% above its average consensus analyst price target of $112.19. Laboratory Corp of America Holdings shares have support at the 50-day moving average (MA) of $105.91 and additional support at the 200-day MA of $103.58.
LH: 116.90 (+0.06)
Global Prenatal and Newborn Genetic Testing Market 2015-2019 with Agilent Technologies, Bio-Rad Laboratories, Illumina & Sequenom Dominating
M2 - Wed Jan 14, 11:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/wbgb7s/global_prenatal) has announced the addition of the "Global Prenatal and Newborn Genetic Testing Market 2015-2019" report to their offering. The Global Prenatal and Newborn Genetic Testing market to grow at a CAGR of 31.91% over the period 2014-2019 Prenatal and newborn genetic testing involves genetic testing before and after birth. Prenatal testing helps detect changes in the fetus before birth. It can reduce a couple's uncertainty or help them decide whether to abort a pregnancy in case of conditions such as Down syndrome, trisomy 18, or an open neural tube defect. The procedure includes two blood tests: one in the first trimester and the next in the second trimester. On the other hand, newborn genetic testing is done just after birth to identify genetic disorders. One key trend emerging in this market is the launch of new tests. For instance, in 2014, Laboratory Corporation of America Holdings launched the informaSeq Prenatal Test. In the same year, Sequenom launched the VisibiliT laboratory-developed test in international markets. According to the report, one of the major drivers of the market is the growing incidence of fetal health-related abnormalities such as Down syndrome, Edward syndrome, neural tube defects, sickle cell anemia, thalassemia, Tay-Sachs disease, spina bifida, cystic fibrosis, cleft palate, muscular dystrophy, and fragile X syndrome. Further, the report states that a decrease in fertility rates worldwide is one of the main challenges that the market faces. This has led to a decline in the number of pregnancies, resulting in a reduction in the demand for prenatal and newborn testing The Global Prenatal and Newborn Genetic Testing market can be divided into two segments: - Diagnostic Techniques - Screening Methods Key Vendors - Agilent Technologies - Bio-Rad Laboratories - Illumina - Sequenom Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Technology - Prenatal Screening Tests - Causes and Risk Factors - Genetic Disorders before Birth - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/wb...l_prenatal
SQNM: 3.62 (unch), A: 40.15 (+0.13), LH: 116.90 (+0.06)
MWI Veterinary: Benefits of Takeover by AmerisourceBergen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 12, 3:58PM CST
On Feb 11, 2015, we issued an updated research report on MWI Veterinary Supply Inc. (MWIV).
ABC: 100.34 (+0.51), MWIV: 189.72 (-0.17), CAH: 86.08 (+0.04), LH: 116.90 (+0.06)
Laboratory Corp of America Holdings Has Returned 11.1% Since SmarTrend Recommendation (LH)
Comtex SmarTrend(R) - Thu Feb 12, 10:31AM CST
SmarTrend identified an Uptrend for Laboratory Corp of America Holdings (NYSE:LH) on December 1st, 2014 at $104.33. In approximately 2 months, Laboratory Corp of America Holdings has returned 11.08% as of today's recent price of $115.90.
LH: 116.90 (+0.06)
'Opportunity Strategy' - 6 Months Of Trading Rationale And Analysis
Grey Owl Capital - Seeking Alpha - Thu Feb 12, 1:01AM CST
"Never think that lack of variability is stability. Don't confuse lack of volatility with stability, ever." - Nassim Nicholas Taleb Over the past seven months the price of oil has plunged from a peak above $100/barrel to the mid-$40s...
LUK: 23.50 (-0.01), DNOW: 25.64 (+0.70), EXC: 33.51 (-0.93), UPL: 15.67 (+0.84), NOV: 53.36 (+0.80), POST: 48.62 (-0.25), COG: 28.10 (+0.18), BAX: 70.39 (+0.31), AAL: 48.39 (+0.51), LH: 116.90 (+0.06), ENB: 49.37 (-0.22), VWO: 41.78 (+0.42), BRG: 13.65 (+0.31), BRK.B: 148.34 (-1.45), AAPL: 127.08 (+0.62)
Teledyne Technologies Set to Join the S&P MidCap 400; Popeyes Louisiana Kitchen, Iridium Communications to Join the S&P SmallCap 600
PR Newswire - Tue Feb 10, 5:04PM CST
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices:
DRIV: 25.99 (+0.06), IRDM: 9.46 (+0.11), TDY: 100.91 (+1.11), LH: 116.90 (+0.06), MHFI: 102.19 (unch), PLKI: 61.07 (+0.44), CVD: 107.08 (+0.05)
LabCorp Launches New Patient-Centric Diabetes Report
Business Wire - Tue Feb 10, 7:45AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today the availability of a new Diabetes Patient Education report for type 2 diabetes patients that aligns with the American Diabetes Association (Association) "Standards of Medical Care in Diabetes - 2015," which was published as a supplement to the January 2015 edition of the Association's Diabetes Care journal. LabCorp's Diabetes Patient Education report is a patient-specific education tool that graphically displays results for key tests used to monitor diabetes and its complications, such as hemoglobin A1c (HbA1c), LDL cholesterol, and urine albumin. The report provides, in patient-friendly terms, guidance to help understand test results and suggestions on how to maintain or improve diabetes control and overall cardiovascular risk, focusing on dietary and lifestyle changes. These reports can be conveniently ordered by clinicians treating patients with elevated HbA1c results or a diagnosis of type 2 diabetes. The reports are part of a suite of decision support tools available from LabCorp to assist clinicians and patients in the management of common chronic diseases, such as cardiovascular disease, chronic kidney disease and now, type 2 diabetes.
LH: 116.90 (+0.06)
Watch for Laboratory Corp of America Holdings to Potentially Rebound After Falling 1.33% Yesterday
Comtex SmarTrend(R) - Mon Feb 09, 5:04PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $113.01 to a high of $115.23. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $114.72 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 116.90 (+0.06)
Look for Shares of Laboratory Corp of America Holdings to Potentially Rebound after Yesterday's 1.33% Sell Off
Comtex SmarTrend(R) - Mon Feb 09, 5:03PM CST
Laboratory Corp of America Holdings (NYSE:LH) traded in a range yesterday that spanned from a low of $113.01 to a high of $115.23. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $114.72 on volume of 1.2 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
LH: 116.90 (+0.06)
Steris Tops Q3 Earnings, Revenues; Cuts FY15 Top-Line View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:54AM CST
Steris Corp. (STE) reported third-quarter fiscal 2015 adjusted earnings of 79 cents per share, up 33.9% from the year-ago level.
STE: 65.50 (-0.35), CAH: 86.08 (+0.04), LH: 116.90 (+0.06), MMSI: 17.27 (-0.16)
Becton, Dickinson Beats Q1 Earnings, Revenue Outlook Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:48AM CST
Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2015 EPS of $1.53, which beat the Zacks Consensus Estimate by a dime.
BDX: 143.71 (+0.72), CAH: 86.08 (+0.04), LH: 116.90 (+0.06), MMSI: 17.27 (-0.16)
Covance Earnings in Line, LabCorp Merger Awaits Closure - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 05, 8:36AM CST
Covance (CVD) delivered a healthy performance in the quarter, breaking all prior records, specifically with fourth quarter adjusted net orders amounting to $823 million.
ABCO: 53.69 (+0.32), BEAT: 10.36 (+0.20), LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Covance Reports Fourth Quarter Net Revenue Of $634 Million, Pro Forma EPS Of $0.97 And Record Adjusted Net Orders Of $823 Million
PR Newswire - Wed Feb 04, 6:30AM CST
Covance Inc. (NYSE: CVD) today reported results for its fourth quarter ended December 31, 2014. Net revenue was $634 million, representing 1.8% growth on a GAAP basis from the fourth quarter of 2013. When adjusting for the impact of foreign exchange and the divestitures of the Seattle genomics laboratory and antibody products service line and the acquisition of Medaxial in 2014, revenue growth was 5.3% versus the fourth quarter of 2013. On a GAAP basis, the company reported earnings of $0.91 per diluted share in the fourth quarter. The company reported pro forma earnings per diluted share of $0.97, up 11.9% over the fourth quarter of 2013. Pro forma results exclude charges associated with restructuring and other cost reduction actions and expenses incurred in connection with the planned merger with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) totaling $5.6 million or $0.06 per share.
LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Icon, A Leader In Its Industry, Builds A Base
at Investor's Business Daily - Tue Jan 27, 5:12PM CST
New drugs require clinical trials and those trials increasingly have taken place on an international stage. Many top drug developers outsource an increasing share of trials to companies like Icon (ICLR). Based in Dublin, Icon is one of the top five...
PRXL: 62.91 (-0.18), Q: 63.31 (+0.06), LH: 116.90 (+0.06), ICLR: 60.01 (+0.38), CVD: 107.08 (+0.05)
LabCorp plans sale of senior notes in four tranches
M2 - Thu Jan 22, 7:10AM CST
Diagnostic technologies company Laboratory Corporation of America Holdings (NYSE:LH) said on Wednesday that it intends to issue senior notes in four tranches with maturities of five,seven,ten and 30 years, respectively (the notes).
LH: 116.90 (+0.06)
LabCorp prices debt offering
Seeking Alpha - at Seeking Alpha - Thu Jan 22, 6:20AM CST
LH: 116.90 (+0.06)
LabCorp Prices $500,000,000 in 2.625% Senior Notes Due 2020, $500,000,000 in 3.200% Senior Notes Due 2022, $1,000,000,000 in 3.600% Senior Notes Due 2025 and $900,000,000 in 4.700% Senior Notes Due 2045
Business Wire - Wed Jan 21, 6:41PM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that it has priced its offering of $2.9 billion in senior notes. The offering consists of four tranches: $500,000,000 aggregate principal amount of 2.625% Senior Notes due 2020 (the "2020 Notes"
, $500,000,000 aggregate principal amount of 3.200% Senior Notes due 2022 (the "2022 Notes" , $1,000,000,000 aggregate principal amount of 3.600% Senior Notes due 2025 (the "2025 Notes" and $900,000,000 aggregate principal amount of 4.700% Senior Notes due 2045 (together with the 2020 Notes, the 2022 Notes and the 2025 Notes, the "Notes" . The Notes will bear interest from January 30, 2015, payable semi-annually on February 1 and August 1, commencing on August 1, 2015. The closing of the offering is expected to occur on January 30, 2015, subject to the satisfaction of customary closing conditions. The Notes will be senior unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt. LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
LabCorp Announces Proposed Sale of Senior Notes
Business Wire - Wed Jan 21, 7:59AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) announced today that it plans to offer, subject to market and other conditions, senior notes that are expected to be issued in four tranches with maturities of 5,7,10 and 30 years, respectively (the "Notes"
. The Notes will be senior unsecured obligations and will rank equally with LabCorp's existing and future senior unsecured debt. LH: 116.90 (+0.06), CVD: 107.08 (+0.05)
Technical Snapshot on Health Care Services Stocks -- Express Scripts Holding, Quest Diagnostics, Laboratory Corp. of America, Catamaran, and DaVita HealthCare Partners
PR Newswire - Wed Jan 21, 7:30AM CST
Investor-Edge has initiated coverage on the following equities: Express Scripts Holding Company (NASDAQ: ESRX), Quest Diagnostics Inc. (NYSE: DGX), Laboratory Corporation of America Holdings (NYSE: LH), Catamaran Corporation (NASDAQ: CTRX), and DaVita HealthCare Partners Inc. (NYSE: DVA). Free research report on Express Scripts Holding can be accessed at http://get.Investor-Edge.com/pdf/?c=Express%2...amp;s=ESRX. On Tuesday, January 20, 2015, the NASDAQ Composite ended at 4,654.85, up 0.44%, the Dow Jones Industrial Average advanced 0.02%, to finish the day at 17,515.23, and the S&P 500 closed at 2,022.55, up 0.15%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 814.01, down 0.08%, while the index has advanced 14.99% in the previous three months. Register for your complimentary reports at the links given below.
CTRX: 53.24 (+0.65), ESRX: 84.90 (+0.40), DVA: 73.10 (-3.29), DGX: 71.68 (+0.03), LH: 116.90 (+0.06)
Upgrade Alert for Laboratory Corp of America Holdings (LH)
Comtex SmarTrend(R) - Wed Jan 21, 7:03AM CST
Laboratory Corp of America Holdings (NYSE:LH) was upgraded from Hold to Buy at Evercore ISI today. The stock closed yesterday at $117.23 on volume of 1.1 million shares, below average daily volume of 1.5 million. Laboratory Corp of America Holdings (NYSE:LH) is currently priced 4.3% above its average consensus analyst price target of $112.19. Laboratory Corp of America Holdings shares have support at the 50-day moving average (MA) of $105.91 and additional support at the 200-day MA of $103.58.
LH: 116.90 (+0.06)
Global Prenatal and Newborn Genetic Testing Market 2015-2019 with Agilent Technologies, Bio-Rad Laboratories, Illumina & Sequenom Dominating
M2 - Wed Jan 14, 11:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/wbgb7s/global_prenatal) has announced the addition of the "Global Prenatal and Newborn Genetic Testing Market 2015-2019" report to their offering. The Global Prenatal and Newborn Genetic Testing market to grow at a CAGR of 31.91% over the period 2014-2019 Prenatal and newborn genetic testing involves genetic testing before and after birth. Prenatal testing helps detect changes in the fetus before birth. It can reduce a couple's uncertainty or help them decide whether to abort a pregnancy in case of conditions such as Down syndrome, trisomy 18, or an open neural tube defect. The procedure includes two blood tests: one in the first trimester and the next in the second trimester. On the other hand, newborn genetic testing is done just after birth to identify genetic disorders. One key trend emerging in this market is the launch of new tests. For instance, in 2014, Laboratory Corporation of America Holdings launched the informaSeq Prenatal Test. In the same year, Sequenom launched the VisibiliT laboratory-developed test in international markets. According to the report, one of the major drivers of the market is the growing incidence of fetal health-related abnormalities such as Down syndrome, Edward syndrome, neural tube defects, sickle cell anemia, thalassemia, Tay-Sachs disease, spina bifida, cystic fibrosis, cleft palate, muscular dystrophy, and fragile X syndrome. Further, the report states that a decrease in fertility rates worldwide is one of the main challenges that the market faces. This has led to a decline in the number of pregnancies, resulting in a reduction in the demand for prenatal and newborn testing The Global Prenatal and Newborn Genetic Testing market can be divided into two segments: - Diagnostic Techniques - Screening Methods Key Vendors - Agilent Technologies - Bio-Rad Laboratories - Illumina - Sequenom Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Technology - Prenatal Screening Tests - Causes and Risk Factors - Genetic Disorders before Birth - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/wb...l_prenatal
SQNM: 3.62 (unch), A: 40.15 (+0.13), LH: 116.90 (+0.06)
